Supernus Pharmaceuticals Reports Executive Changes and Compensation Arrangements
Ticker: SUPN · Form: 8-K · Filed: 2024-02-21T00:00:00.000Z
Sentiment: neutral
Topics: executive-changes, compensatory-arrangements, corporate-governance
TL;DR
**Supernus Pharmaceuticals just filed an 8-K about executive changes and pay, so keep an eye out for potential strategic shifts.**
AI Summary
Supernus Pharmaceuticals, Inc. filed an 8-K on February 21, 2024, reporting an event on February 14, 2024, concerning the departure or election of directors or officers and their compensatory arrangements. The filing indicates a change in leadership or executive compensation, which is a routine disclosure for public companies. The company's business address is 9715 Key West Ave, Rockville, MD 20850.
Why It Matters
Changes in executive leadership and compensation can signal strategic shifts or financial health, impacting investor confidence and future company direction.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure about executive changes and compensation, not indicating any immediate financial distress or major operational risks.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- February 14, 2024 (date) — Date of earliest event reported
- February 21, 2024 (date) — Filed as of date
- 9715 Key West Ave, Rockville, MD 20850 (company) — Business address
- 001-35518 (company) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 14, 2024.
What is the primary subject matter of this 8-K filing?
The primary subject matter of this 8-K filing is the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 21, 2024.
What is the business address of Supernus Pharmaceuticals, Inc.?
The business address of Supernus Pharmaceuticals, Inc. is 9715 Key West Ave, Rockville, MD 20850.
What is Supernus Pharmaceuticals, Inc.'s Commission File Number?
Supernus Pharmaceuticals, Inc.'s Commission File Number is 001-35518.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-02-20 18:14:07
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20240214.htm (8-K) — 24KB
- 0001356576-24-000009.txt ( ) — 147KB
- supn-20240214.xsd (EX-101.SCH) — 2KB
- supn-20240214_lab.xml (EX-101.LAB) — 24KB
- supn-20240214_pre.xml (EX-101.PRE) — 12KB
- supn-20240214_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 14, 2024, Tami T. Martin, R.N., Esq., the Company's Senior Vice President, Regulatory Affairs, notified Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") of her retirement from the Company effective May 3, 2024. The Company expects Roman Bradel, Ph.D. to join the Company in March 2024 as its Vice President, Regulatory Affairs reporting to Frank Mottola, the Company's Senior Vice President, Quality, GMP Operations and IT. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: February 20, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3